Characterization of DNA-hyaluronan matrix for sustained gene transfer.

DNA-Hyaluronan (DNA-HA) matrix formulations intended for use as gene delivery systems have been developed and their potential for delivering DNA encoding a model therapeutic cytokine, platelet-derived growth factor (PDGF), has been evaluated. The results of enzyme-mediated release kinetics studies suggested that the rate of DNA release from the DNA-HA matrices could be modulated by changing the DNA loading or the degree of crosslinking. SEM imaging of the DNA-HA matrix showed that it was gradually eroded by enzymatic action. The results of gel electrophoresis suggested that there was some degree of interaction between DNA and native HA and that portions of the DNA released from the DNA-HA matrices were associated with crosslinked HA fragments. Only fractions of the DNA released from the DNA-HA matrices were free and the rest was entrapped by HA fragments, which could serve as a mechanism for DNA protection. The results from cell transfection studies using DNA samples collected during the course of release studies confirmed this hypothesis. The PDGF produced by transfection of the DNA released from DNA-HA matrices induced human dermal fibroblast cells to proliferate.

[1]  C. Benz,et al.  Growth factors and their receptors. , 1994, Hematology/oncology clinics of North America.

[2]  G. Prestwich,et al.  Biotinylated hyaluronic acid: a new tool for probing hyaluronate-receptor interactions. , 1994, Bioconjugate chemistry.

[3]  Anita B. Roberts,et al.  Peptide Growth Factors and Their Receptors I , 1990, Springer Study Edition.

[4]  J M Davidson,et al.  Hyaluronate derivatives and their application to wound healing: preliminary observations. , 1991, Clinical materials.

[5]  D. Messadi,et al.  Binding and internalization of hyaluronate by human cutaneous fibroblasts. , 1992, Matrix.

[6]  G. Prestwich,et al.  Novel Hydrogels of Hyaluronic Acid: Synthesis, Surface Morphology, and Solid-State NMR , 1994 .

[7]  B. Toole.  Hyaluronan and its binding proteins, the hyaladherins. , 1990, Current opinion in cell biology.

[8]  E. Balazs,et al.  Clinical uses of hyaluronan. , 2007, Ciba Foundation symposium.

[9]  G. Prestwich,et al.  Synthesis and in vitro degradation of new polyvalent hydrazide cross-linked hydrogels of hyaluronic acid. , 1997, Bioconjugate chemistry.

[10]  Alun D. Hughes,et al.  Platelet-derived growth factor (PDGF): actions and mechanisms in vascular smooth muscle. , 1996, General pharmacology.

[11]  K. Paigen,et al.  A simple, rapid, and sensitive DNA assay procedure. , 1980, Analytical biochemistry.

[12]  W. Mark Saltzman,et al.  Synthetic DNA delivery systems , 2000, Nature Biotechnology.

[13]  G. Prestwich,et al.  Functionalized derivatives of hyaluronic acid oligosaccharides: drug carriers and novel biomaterials. , 1994, Bioconjugate chemistry.

[14]  L. Juhlin.  Hyaluronan in skin , 1997, Journal of internal medicine.

[15]  K. Goa,et al.  Hyaluronic acid. A review of its pharmacology and use as a surgical aid in ophthalmology, and its therapeutic potential in joint disease and wound healing. , 1994, Drugs.

[16]  R. Kirsner,et al.  Techniques of split-thickness skin grafting for lower extremity ulcerations. , 1993, The Journal of dermatologic surgery and oncology.

[17]  C. Chauzy,et al.  An indirect enzymoimmunological assay for hyaluronidase. , 1987, Journal of immunological methods.

[18]  C. Heldin,et al.  Signal transduction via platelet-derived growth factor receptors. , 1998, Biochimica et biophysica acta.